All posts by Matthias

TRACT Therapeutics, Inc. Launches the TRACT CryoBanking Program™ to Collect and Bank a Patient’s Immune Cells for Future Treatment

May 31, 2016 08:58 AM Central Daylight Time CHICAGO (BUSINESS WIRE) – TRACT Therapeutics, Inc., a biotechnology company developing personalized regulatory Tcell (Treg) therapy, announced today that it has launched the TRACT CryoBanking Program to enable individuals to donate their blood consisting of their immune cells for future treatments as Continue reading

TRACT Therapeutics, Inc. Received FDA Approval for a Phase 2 Trial Using a Patient’s Immune Cells to Prevent Organ Rejection

April 29, 2016 15:07 UTC CHICAGO–(BUSINESS WIRE)– TRACT Therapeutics, Inc., a biotechnology company developing personalized regulatory T-cell (Treg) therapy, announced today that it received Food and Drug Administration (FDA) approval to initiate a Phase 2 clinical trial to investigate the efficacy and safety of its novel therapy for kidney transplant Continue reading